Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ: IONS )

33.53 +0.12 (+0.37%)
Streaming Delayed Price Updated: 9:58 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,156
Open 33.34
Bid (Size) 33.49 (2)
Ask (Size) 33.59 (2)
Prev. Close 33.41
Today's Range 32.91 - 33.84
52wk Range 30.23 - 52.34
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales. 
Via Benzinga
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-3.33%
-3.33%
1 Month
+6.53%
+6.53%
3 Month
-11.73%
-11.73%
6 Month
-21.15%
-21.15%
1 Year
-22.32%
-22.32%

More News

Read More
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
Via Benzinga
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharma Beats Expectations for Q4
Via The Motley Fool
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
Via Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
Via Benzinga
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Via Benzinga
Ionis reports fourth quarter and full year 2024 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold fourth quarter and full year 2024 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Via Investor's Business Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.